New Horizons in Microbiota and Metabolic Health Research
New Horizons in Microbiota and Metabolic Health Research
复制标题
微生物群与代谢健康研究的新视野
DOI：
10.1210/clinem/dgaa769
复制
发表时间：
2021-01-23
影响因子：
5.8
通讯作者：
Yadav, Hariom
中科院分区：
文献类型：
--
作者：
Mishra, Sidharth P.;Jain, Shalini;Yadav, Hariom
数十年的研究表明，生活在我们肠道中的微生物（微生物群）有助于维持正常的代谢功能和肥胖和糖尿病等代谢疾病的病理。新的证据表明，肠道微生物群影响饮食和药物的个性化效果，并影响肠脑轴和肠漏炎症，从而控制代谢功能/疾病。肠道微生物群可以成为代谢疾病预后标志物和治疗的理想来源。在这里，我们讨论个性化营养、药物反应和疾病预后中微生物群和代谢相互作用领域的新兴概念。
Decade-old studies have demonstrated that microbes living in our gut (microbiota) contribute to both maintaining normal metabolic function and to the pathology of metabolic diseases, such as obesity and diabetes. Emerging evidence suggests that gut microbiota influences the personalized effects of diets and drugs and impact the gut-brain axis and leaky gut inflammation to control metabolic function/diseases. Gut microbiota can be an ideal source of prognostic markers and therapies for metabolic diseases. Here we discuss the emerging concepts in the area of microbiota and metabolic interactions in personalized nutrition, drug response, and disease prognosis.